Sukumar Nagendran Sells 1,780 Shares of AveXis Inc (AVXS) Stock

AveXis Inc (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total transaction of $195,301.60. Following the completion of the transaction, the vice president now owns 1,780 shares in the company, valued at $195,301.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sukumar Nagendran also recently made the following trade(s):

  • On Friday, December 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $94.77, for a total transaction of $168,690.60.
  • On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $101.26, for a total transaction of $180,242.80.

Shares of AveXis Inc (NASDAQ:AVXS) opened at $102.08 on Friday. AveXis Inc has a 12 month low of $50.56 and a 12 month high of $116.15.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the company earned ($0.87) EPS. sell-side analysts anticipate that AveXis Inc will post -6.23 earnings per share for the current year.

A number of equities analysts have commented on AVXS shares. Citigroup set a $132.00 price target on shares of AveXis and gave the company a “buy” rating in a research report on Friday. Canaccord Genuity set a $110.00 price target on shares of AveXis and gave the company a “hold” rating in a research report on Wednesday, December 20th. BidaskClub lowered shares of AveXis from a “hold” rating to a “sell” rating in a research report on Thursday, December 14th. Bank of America reduced their price target on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $130.00 target price (up from $123.00) on shares of AveXis in a research report on Thursday, October 12th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $111.94.

Several institutional investors and hedge funds have recently bought and sold shares of AVXS. Schwab Charles Investment Management Inc. raised its stake in shares of AveXis by 57.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 86,520 shares of the company’s stock worth $7,109,000 after buying an additional 31,655 shares during the last quarter. Rhumbline Advisers raised its stake in shares of AveXis by 234.5% during the second quarter. Rhumbline Advisers now owns 22,682 shares of the company’s stock worth $1,864,000 after buying an additional 15,901 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of AveXis during the second quarter worth approximately $1,315,000. SG Americas Securities LLC raised its stake in shares of AveXis by 28.2% during the second quarter. SG Americas Securities LLC now owns 5,111 shares of the company’s stock worth $420,000 after buying an additional 1,124 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of AveXis by 79.9% during the second quarter. Bank of New York Mellon Corp now owns 113,225 shares of the company’s stock worth $9,302,000 after buying an additional 50,303 shares during the last quarter. 92.88% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/06/sukumar-nagendran-sells-1780-shares-of-avexis-inc-avxs-stock.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

What are top analysts saying about AveXis? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AveXis and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit